The Prominin-1-Derived Peptide Improves Cardiac Function Following Ischemia

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Molecular Biology

Background:

• Myocardial infarction (MI) is a leading cause of death globally.
• Current revascularization therapies have limitations for many patients.
• Previous attempts using exogenous Vascular Endothelial Growth Factor (VEGF) have faced challenges with half-life and toxicity.

Purpose of the Study:

• To investigate the efficacy of PR1P, a novel peptide that stabilizes and upregulates endogenous VEGF, in improving outcomes following MI.
• To test the hypothesis that PR1P can serve as a non-invasive therapeutic for MI.

Main Methods:

• Myocardial infarction was induced in mice and rats via left coronary artery ligation.
• Animals were treated with PR1P or a scrambled peptide every other day for 14 days.
• Cardiac function was assessed using hemodynamic monitoring and echocardiography; molecular and histological analyses were performed.

Main Results:

• PR1P treatment significantly improved key functional markers of heart function, including stroke volume and cardiac output in both mice and rats.
• Molecular and histological analyses confirmed that PR1P targeted, stabilized, and upregulated endogenous VEGF within the ischemic myocardium.
• PR1P demonstrated a therapeutic effect by enhancing the body's natural VEGF response.

Conclusions:

• PR1P shows promise as a potential non-invasive therapeutic agent for myocardial infarction.
• The peptide's ability to modulate endogenous VEGF offers a novel strategy for treating ischemic heart disease.
• Further research into PR1P could lead to new treatments for patients unsuitable for conventional therapies.